[Prognostic value of cytokines and neurohormones in severe heart failure]

Bàrbara Vidal1, Eulàlia Roig, Félix Pérez-Villa

  • 1Institut Clínic de Malalties Cardiovasculars, Hospital Clinic de Barcelona, Spain.

Insights

Plasma angiotensin II shows limited accuracy in predicting heart transplant outcomes. Clinical and hemodynamic factors remain crucial for selecting heart transplant candidates with severe heart failure.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Transplantation Medicine

Background:

  • Screening heart transplant candidates is challenging.
  • Elevated cytokines and neurohormones correlate with poor heart failure prognosis.
  • The utility of these markers for heart transplant selection is unestablished.

Purpose of the Study:

  • To evaluate the prognostic value of plasma neurohormone levels in patients with severe systolic heart failure.
  • To determine if specific biomarkers can identify candidates for heart transplantation.

Main Methods:

  • Assessed plasma levels of aldosterone, atrial natriuretic peptide, plasma renin activity, angiotensin II, norepinephrine, endothelin, interleukin-6, and tumor necrosis factor-alpha in 83 patients.
  • Patients had systolic left ventricular dysfunction and New York Heart Association functional class III-IV.

Main Results:

  • Over one year, 13 patients died and 26 received heart transplants.
  • Univariate analysis linked angiotensin II, norepinephrine, plasma renin activity, systolic blood pressure, and ventricular diameters to poor prognosis.
  • Multivariate analysis identified low cardiac index, plasma angiotensin II, and pulmonary capillary wedge pressure as independent predictors of adverse outcomes.

Conclusions:

  • Plasma angiotensin II demonstrated moderate sensitivity and specificity for predicting death or the need for heart transplantation.
  • Despite being the best neurohormone marker, angiotensin II's predictive power was limited.
  • Clinical and hemodynamic parameters should guide heart transplant decisions.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...